Grifols S.A. ADR Stock
Grifols S.A. ADR Stock
We can see a decrease in the price for Grifols S.A. ADR. Compared to yesterday it has lost -€0.200 (-2.650%).
Pros and Cons of Grifols S.A. ADR in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Grifols S.A. ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Grifols S.A. ADR | -2.650% | -4.430% | 1.342% | 10.219% | -0.658% | -9.581% | -53.862% |
| Beximco Pharmaceuticals Ltd. GDR | 0.000% | 8.333% | 5.691% | 21.495% | 16.071% | -1.887% | -47.739% |
| Eledon Pharmaceuticals Inc. | 1.150% | 21.678% | 33.846% | -54.688% | 35.938% | -43.871% | -85.452% |
| SELLAS Life Sciences Group Inc | -1.900% | -3.693% | 68.657% | 227.220% | 19.577% | 21.375% | -30.971% |
Comments
Grifols, S.A. (NASDAQ: GRFS) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for GRFS provided by MarketBeat
Grifols, S.A. (NASDAQ: GRFS) was downgraded by analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating.
Show more
Ratings data for GRFS provided by MarketBeat
Grifols, S.A. (NASDAQ: GRFS) is now covered by analysts at Morgan Stanley. They set an "overweight" rating on the stock.
Show more
Ratings data for GRFS provided by MarketBeat